Increasing Investment in Research and Development Boosts Endometriosis Treatment Market, Estimated CAGR of 3% by 2030 | FMI

Endometriosis Treatment Market

Increasing investments in the Endometriosis Treatment Market by key stakeholders and rising awareness among women are the major factors expected to drive market growth. The global endometriosis treatment market was valued at US$ 2.8 Bn in 2018 and is expected to exhibit a CAGR of around 3% over the forecast period (2019-2030).

The rising prevalence of endometriosis condition has fueled the demand for endometriosis treatment across the world. High focus on the introduction of therapeutically-advanced endometriosis treatment options is expected to propel the growth of the market over the forecast period. Leading industry players are significantly accelerating the development of scientific and clinical therapeutic agents and new product launches in the global endometriosis treatment market. This considerable push by industry players is expected to drive future market growth.

Embrace the power of visuals – claim your complimentary report. @
https://www.futuremarketinsights.com/reports/sample/rep-gb-3870

Key Takeaways of Endometriosis Treatment Industry Study

  • Based on drug, oral contraceptives contributed maximum value share to the global endometriosis treatment Industry in 2018, owing to high preference for them as a first-line therapy for patients without contraindications, and efficacy in preventing recurrence of pelvic pain and endometriosis lesions.
  • High treatment efficacy and acceptance with low risk are expected to result in notable share of hormonal therapy in the treatment type.
  • The hospital pharmacies and retail pharmacies segments, collectively, hold above 60% of value share to the endometriosis treatment market, owing to the high patient pool in hospitals and visiting retail pharmacies.
  • Europe captured a notable revenue share of 37% in 2018, and is expected to be the most lucrative region in the global endometriosis treatment market during the forecast period.
  • Increasing government expenditure for high growth of the medical industry in emerging economies in the Asian region is expected to drive the growth of the endometriosis treatment market across this region.

Multiple New Indications – Imperative Strategy for Market Players

Increasing the introduction of endometriosis drugs with multiple new indications is a major factor responsible for intense competition among market players. Several companies are focusing on launching new endometriosis treatment options to increase their product sales and expand their market share. For example, in July 2018, AbbVie Inc. introduced a new innovative product – Orilissa™ (elagolix) tablets, a gonadotropin-releasing hormone (GnRH) receptor antagonist for the management of moderate to severe pain associated with endometriosis, in the U.S. market.

What else is in the report?

Future Market Insights (FMI) offers a unique perspective and actionable insights on the endometriosis treatment market in its latest study, presenting historical demand assessment of 2014-2018 and projections for the period of 2019-2030, based on drug (oral contraceptives, progestins, NSAIDs, GnRH analogues, LNR-IUDs, and others), treatment type (hormonal therapy and pain management), and distribution channel (hospital pharmacies, retail pharmacies, drugstores, and e-Commerce), across seven key regions of the world.

Unveil new perspectives through our innovative methodology. @
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-3870

Market segmentation

The global endometriosis treatment market is segmented in detail to cover every aspect of the market and present a complete market intelligence approach to the reader.

Drug:

  • Oral Contraceptives
  • Progestins
  • NSAIDs
  • GnRH Analogues
  • LNR-IUDs
  • Others

Treatment Type:

  • Hormonal Therapy
  • Pain Management

Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Drugstores
  • e-Commerce

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, Stevie Award – recipient market research organization and a member of Greater New York Chamber of Commerce) provides in-depth insights into governing factors elevating the demand in the market. It discloses opportunities that will favour the market growth in various segments based on Source, Application, Sales Channel and End Use over the next 10-years.

Contact Us:          

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedInTwitterBlogsYouTube

About the Author

Nikhil Kaitwade

Associate Vice President at Future Market Insights, Inc. has over a decade of experience in market research and business consulting. He has successfully delivered 1500+ client assignments, predominantly in Automotive, Chemicals, Industrial Equipment, Oil & Gas, and Service industries.
His core competency circles around developing research methodology, creating a unique analysis framework, statistical data models for pricing analysis, competition mapping, and market feasibility analysis. His expertise also extends wide and beyond analysis, advising clients on identifying growth potential in established and niche market segments, investment/divestment decisions, and market entry decision-making.
Nikhil holds an MBA degree in Marketing and IT and a Graduate in Mechanical Engineering. Nikhil has authored several publications and quoted in journals like EMS Now, EPR Magazine, and EE Times.

Leave a Reply

Your email address will not be published. Required fields are marked *

You may also like these